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phropathy, and blockade of the RAS by ramipril may conferLong-term treatment with ramipril attenuates renal osteopon-
renoprotection by decreasing OPN expression in non–insulin-tin expression in diabetic rats.
dependent diabetic nephropathy.Background. Osteopontin (OPN) mediates progressive re-
nal injury in various renal diseases by attracting macrophages,
and its expression is regulated by the renin-angiotensin system
(RAS). We studied the association between OPN expression and
Diabetic nephropathy is characterized by a progressivetubulointerstitial injury, and investigated the effect of ramipril
accumulation of extracellular matrix components in theon OPN expression in an animal model of non–insulin-depen-
dent diabetes mellitus (NIDDM): Otsuka Long-Evans Toku- glomerular mesangium and tubular interstitium, which
shima Fatty (OLETF) rats. eventually leads to proteinuria and renal failure [1, 2]. It
Methods. Control (Long-Evans Tokushima Otsuka, LETO)
is generally accepted that tubulointerstitial injury, alongand diabetic (OLETF) rats were treated with ramipril (3 mg/kg
with glomerulosclerosis, is a major feature and an impor-in drinking water) or vehicle for nine months, starting at 20
weeks of age. Systolic blood pressure, body weight, urinary pro- tant predictor of renal dysfunction in diabetic nephropa-
tein excretion and oral glucose tolerance tests (OGTT) were thy [3, 4]. The mechanisms underlying the evolution of
monitored periodically. Renal function, histology (glomerulo- diabetic nephropathy are extremely complex, and sev-sclerosis, tubulointerstitial fibrosis, and ED-1-positive cells as
eral mediators have been implicated. Of these, chemo-a measure of macrophage infiltration), and expressions of OPN
attractants and infiltrated macrophages have been pro-and transforming growth factor-1 (TGF-1) were evaluated
at the end of the study. posed to be important players [5–7].
Results. Compared with the LETO rats, OLETF rats showed Osteopontin (OPN) is a molecule that mediates cell
declines in creatinine clearance rate, increases in urinary pro-
adhesion and migration and functions by binding avidly totein excretion and systolic blood pressure, and development
a number of ligands, including v3 integrin, CD44, colla-of glomerulosclerosis, tubulointerstitial fibrosis, and inflam-
matory cell infiltration (all P  0.05). Blocking angiotensin II gen type I, and fibronectin [8, 9]. Many types of cells, in-
with ramipril significantly improved all of these parameters cluding osteoclasts, some epithelial cells, macrophages,
(all P  0.01). At the molecular level, expressions of OPN T cells, smooth muscle cells, and some tumors [10–15], ex-and TGF-1 were up-regulated in the OLETF rats, and were
press OPN in a constitutive or inducible fashion. A func-markedly suppressed following ramipril treatment. The sites
of strong OPN mRNA and protein expressions were localized tional role for OPN with respect to attracting macro-
to areas of renal injury. Of note, the expression of OPN mRNA phages has been recently documented in vivo and in
was strongly correlated with the number of ED-1-positive cells vitro [16, 17]. The up-regulation of OPN expression is(r  0.560, P  0.01) and the tubulointerstitial fibrosis score
also closely associated with macrophage influx in several(r  0.500, P  0.05).
models of kidney disease [18–20]. Moreover, the extentConclusions. Up-regulation of OPN expression may play a
role in tubulointerstitial injury associated with diabetic ne- of up-regulation of OPN expression in tubules correlates
with the degree of macrophage accumulation and the
magnitude of tubulointerstitial fibrosis and renal dys-Key words: osteopontin, macrophage, ramipril, tubulointerstitial in-
jury, OLETF, renin-angiotensin system, TGF-, renoprotection. function [21].
Based on the above findings, we hypothesized that
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sion is influenced by the renin-angiotensin system (RAS). before and 30, 60, 90, and 120 minutes after the OGTT
from the tail vein as previously described [25]. All ani-To test this hypothesis, we examined the role of the RAS
in regulating OPN by administering the angiotensin-con- mals were caged individually for 24-hour urine collection
at before and three, six, and nine months. Urinary pro-verting enzyme (ACE) inhibitor ramipril in a newly es-
tablished animal model: Otsuka Long-Evans Tokushima tein excretion (UprotE) was estimated using the sulfosali-
cylic acid method. Blood samples were also obtainedFatty (OLETF) rats, a strain showing spontaneous non–
insulin-dependent diabetes mellitus (NIDDM) [22–25]. before euthanizing the rats at nine months. The creati-
nine clearance rate (CCr) was calculated using a standardUsing this animal model, we clearly demonstrate an asso-
ciation between the RAS and OPN in the development formula.
of type II diabetic nephropathy.
Histology
The kidney specimens were fixed in Periodate-lysine-
METHODS
paraformaldehyde (PLP) solution and embedded in wax.
Animals and drugs Four-micrometer sections were processed and stained with
periodic acid-Schiff (PAS) reagent and Masson trichrome.Age-matched male OLETF and Long-Evans Toku-
shima Otsuka (LETO) rats were provided by Otsuka Glomerulosclerosis was assessed on PAS-stained sections
using a semiquantitative score from 0 to 4 [26]: gradePharmaceutical Tokushima Research Institute (Toku-
shima, Japan). Animals were housed in cages (Nalge Co., 0 no sclerosis; grade 1 sclerosis up to 25% of glomer-
uli; grade 2  sclerosis from 25% to 50% of glomeruli;Rochester, NY, USA) under a temperature and light-
controlled environment, and allowed free access to stan- grade 3 sclerosis from 50% to 75% of glomeruli; grade
4  sclerosis more than 75% of glomeruli. More thandard laboratory chow (Teklad Premier) and tap water.
Ramipril (Hoechst AG, Frankfurt, Germany) was admin- 50 glomeruli were analyzed for each rat. For evaluating
tubulointerstitial fibrosis, a minimum of 20 fields peristered in drinking water at a daily dose of 3 mg/kg [48].
section (trichrome stained) was evaluated using a color
Research design image analyzer (Mustek Paragon 800 SP, Macintosh
PowerPC 7100 running NIH image V. 1.5 software). TheForty rats at 20 weeks of age were assigned randomly
into four subgroups and treated daily with ramipril or extent of tubulointerstitial fibrosis was evaluated by
counting the percentage of areas injured per field ofvehicle for nine months:
cortex. Scores from 0 to 3 were used: 0 normal intersti-
tium; 0.5  5% of areas injured; 1  5 to 15% of areas(1) LETO controls (L  C, N  10) received vehicle
(drinking water); injured; 1.5  16 to 25% of areas injured; 2  26 to 35%
of areas injured; 2.5  36 to 45% of areas injured; 3 (2) LETO ramipril-treated rats (L  R, N  10) re-
ceived ramipril (3 mg/kg in drinking water); 45% of areas injured [27]. Histological analyses were
performed in randomly selected cortical fields of sections(3) OLETF controls (OLC, N 10) received vehi-
cle (drinking water); by a pathologist who was blinded to the identity of the
treatment groups.(4) OLETO ramipril-treated rats (OL  R, N  10)
received ramipril (3 mg/kg in drinking water).
Northern blots of osteopontin and TGF-1
A 1 kb cRNA probe was generated from 2B7 cDNAAt the end of the experiment, all animals were eutha-
nized with ketamine, and kidney tissues were removed clone of rat smooth muscle OPN [11]. Sense and anti-
sense cRNA probe were labeled with digoxigenin (DIG)-rapidly for morphological and molecular examinations.
The experimental protocol and care of animals were UTP using a T7 RNA polymerase kit (Boehringer Mann-
heim GmbH, Mannheim, Germany). Probes were pre-approved by the Animal Care Committee of the Catholic
University of Korea. cipitated and incorporation of DIG was determined by
dot blotting. Northern blotting was performed as pre-
Functional protocol viously reported [28]. Briefly, kidney cortex was homoge-
nized. Total RNA was extracted using the RNAzol re-Body weight was recorded periodically for each rat.
Systolic blood pressure (SBP) was measured in conscious agent (Tel-Test, Inc., TX, USA), and 20 g samples were
denatured with glyoxal and dimethylsulphoxide, size frac-rats every three months using plethysmography using a
tail manometer-tachometer system (BP-2000; Visitech tionated on 1.2% agarose gels and capillary blotted onto
positively-charged nylon membranes (Boehringer Mann-Systems, Apex, NC, USA); at least three readings for
each rat were averaged. An oral glucose tolerance test heim). Membranes were hybridized overnight at 68C
or 42C with DIG-labeled cRNA (or 32P labeled cDNA(OGTT) was performed on rats fasted for 16 hours at the
start and three and nine months. Glucose (2 g) solution probes) in a DIG wash and Block Buffer Set solution
(Boehringer Mannheim). Following hybridization, mem-was given orally to rats, and blood samples were collected
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branes were washed finally in [0.1	 standard saline citrate ilar to that for OPN. The numbers of ED-1 positive cells
(SSC)]/0.1% sodium dodecyl sulfate (SDS) at 68C or were counted in at least 20 fields of cortex per section
(0.2 	 SSC)/0.1% SDS at 42C. Bound probes were under 	200 magnification.
detected using sheet anti-DIG antibody (Fab) conjugated
Statistical analysiswith alkaline phosphatase (Boehringer Mannheim) and
development with CSPD-star enhanced chemilumines- Data are presented as mean 
 SEM. Comparisons
cence (Boehringer Mannheim). The densitometry analy- between groups were performed by one-way ANOVA
sis was performed using the NIH ImagePC program. with post hoc Bonferroni test or repeated measures anal-
Three determinations for each band were averaged and ysis of variance (ANOVA; time course). The Pearson
referenced to glyceraldehyde-3-phosphate dehydroge- single-correlation coefficient was used to compare osteo-
nase (GAPDH; %). Data are expressed as mean
 SEM. pontin mRNA expression with ED-1 positive cells and
tubulointerstitial fibrosis score. Statistical significance
In situ hybridization was accepted when P  0.05.
In situ hybridization was performed on wax-embedded
sections using a microwave-based protocol as previously
RESULTSdescribed [28]. After dewaxing, sections were treated
with a microwave oven for 2 	 5 minutes, incubated Functional findings
with 0.2 mol/L HCl for 15 minutes, followed by 1% As shown in Figure 1A, the OLETF rats became obese
Triton X-100 for 15 minutes, and then digested for 20 from the initiation of treatment and throughout the ex-
minutes with 10 g/mL proteinase-K at 37C (Boeh- perimental period compared with LETO control rats,
ringer Mannheim). Sections were washed in 2 	 SSC, although the body weights of LETO rats also increased
prehybridized, and then hybridized with 0.3 ng/L DIG- gradually with age. Ramipril treatment did not influence
labeled sense or antisense OPN cRNA probe overnight body weights in either treatment groups. OLETF rats
at 37C in a hybridization buffer containing 50% deion- had higher SBP levels than LETO rats at the start of the
ized formamide, 4 	 SSC, 2 	 Denhardt’s solution, experiment (131
 2 vs. 123
 2 mm Hg, P 0.05; Fig. 1B).
1 mg/mL salmon sperm DNA, and 1 mg/mL yeast tRNA. Blockade of angiotensin II (Ang II) with ramipril mark-
Sections were washed finally in 0.1 	 SSC at 37C, and
edly lowered the SBP of OLETF rats throughout treat-
the hybridized probe was detected using sheep anti-DIG
ment versus the untreated OLETF rats (P  0.05).
antibody (Fab) conjugated with alkaline phosphatase
The CCr was significantly lower in OLETF controlsand color development with NBT/ X-phosphate (Boeh-
than in LETO controls (0.16 
 0.01 vs. 0.26 
 0.02 mL/ringer Mannheim). No signal was seen with the sense
min per 100, P  0.05), but ramipril treatment main-riboprobe labeled to the same specific activity.
tained the CCr of OLETF rats to levels similar to those
of LETO rats (Fig. 1C). Levels of UPE were higher inImmunohistochemistry
OLETF rats than in LETO rats at the initiation of studyAfter dewaxing, sections were incubated with 0.5%
(30.3 
 3.1 vs. 17.9 
 1.1 mg/24 h, P  0.05), and in-Triton X 100/PBS solution for 30 minutes and washed
creased progressively throughout the treatment intervalswith phosphate-buffered saline (PBS) three times. Non-
(Fig. 1D). Ramipril treatment decreased the UprotE ofspecific binding sites were blocked with normal horse
OLETF rats at three months compared with the un-serum diluted 1:10 in 0.3% bovine serum albumin (BSA)
treated OLETF rats (31.8 
 1.3 vs. 48.3 
 4.8 mg/24 h,for 30 to 60 minutes, and then incubated for two hours
P  0.01).at 4C in mouse antiserum against OPN (MPIIIB10, ob-
Figure 2 shows plasma glucose responses in the treat-tained from the Developmental Studies Hybridoma
ment groups at zero, three, and nine months. PlasmaBank, University of Iowa, Iowa City, IA, USA) diluted
OGTT responses of LETO rats, whether vehicle- or ram-1:1000 in a humid environment. After rinsing in Tris-
ipril-treated, were within the normal ranges at each timebuffered saline (TBS), sections were incubated in peroxi-
point (Fig. 2A). There were no initial differences in thedase-conjugated rabbit anti-mouse IgG (Amersham Phar-
OGTT responses between LETO and OLETF rats.macia Biotech, Piscataway, NJ, USA), for 30 minutes.
However, at three months, both vehicle- and ramipril-For coloration, sections were incubated with a mixture
treated OLETF rats showed diabetes, as indicated by aof 0.05% 3,3-diaminobenzidine containing 0.01% H2O2
plasma glucose response in the OGTT (Fig. 2B), andat room temperature until a brown color was visible,
the plasma glucose responses in OLETF rats were sig-washed with TBS, counterstained with hematoxylin and
nificantly higher than in LETO rats at nine months (P examined under light microscopy. The procedure of im-
0.05; Fig. 2C). Ramipril treatment did not affect themunostaining for ED-1 (Serotec, Inc., Indianapolis, IN,
plasma glucose concentrations of LETO and OLETFUSA) and transforming growth factor-1 (TGF-1; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was sim- rats in the OGTT at any time point.
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Fig. 1. Body weight (A), systolic blood pressure (B), creatinine clearance (CCr) rate (C ), and urinary protein excretion (D) in OLETF and LETO
rats treated with ramipril or vehicle. Data were obtained from 10 animals per group. Comparisons at different time points were made using
repeated measures ANOVA. Symbols are: () LETO control; () LETO ramipril; () OLETF control; () OLETF ramipril; #P  0.05 vs. LETO
controls; ##P  0.01 vs. OLETF controls; *P  0.05 vs. OLETF-ramipril rats (start of study); **P  0.05 vs. OLETF controls (start of study).
Effects of ramipril on glomerulosclerosis and prominent in the cortical regions of the kidneys of
tubulointerstitial fibrosis OLETF controls versus the LETO controls (1.90 
 0.24
vs. 0.25 
 0.08, respectively; P  0.001). However, thisOLETF rats showed typical histological features of
lesion was significantly attenuated following blockadeglomerulopathy, characterized by thickening of the base-
of Ang II with ramipril (1.00 
 0.17 vs. 1.90 
 0.24,ment membrane, arteriolar hyalinosis, and nodular or
respectively; P  0.002).sclerotic lesions (Fig. 3). Tubulointerstitial fibrosis fea-
tured matrix-rich expansion of the interstitium with dis-
Effects of ramipril on osteopontin mRNA andtortion and collapse of the tubules, and thickening of the
protein expressiontubular basement membranes (Fig. 4). Focal macrophage
Northern blot analysis of the kidney cortex demon-infiltration was observed also within the tubular intersti-
strated a dramatic increase in OPN mRNA in OLETFtium. On our semiquantitative scoring system, OLETF
controls versus LETO controls by the end of the studycontrols showed moderate glomerulosclerosis compared
(705 
 49 vs. 107 
 3%, P  0.001; Fig. 5A), but thiswith the LETO controls (2.7 
 0.3 vs. 0.4 
 0.2, P 
up-regulation of OPN mRNA expression was markedly0.001; Fig. 3). Ramipril treatment significantly delayed
decreased in response to ramipril treatment (298 
 35the development of glomerulosclerosis in OLETF rats
vs. 705 
 49%, P  0.005). To localize OPN mRNA andcompared with the untreated OLETF rats (1.5 
 0.2 vs.
2.7 
 0.3, P  0.004). Tubulointerstitial fibrosis was protein, in situ hybridization and immunohistochemistry
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Fig. 2. Plasma glucose concentrations during oral glucose tolerance test (OGTT) in OLETF and LETO rats treated with ramipril or vehicle at
initiation (A), three months (B), and nine months (C ). Symbols are: () LETO control; () LETO ramipril; () OLETF control; () OLETF
ramipril; #P  0.05 vs. LETO rats.
were performed (Fig. 6). Consistent with previous re- were significantly suppressed. No consistent differences
in OPN mRNA and protein levels between OLETF con-ports [21, 28], in the LETO rats, a much higher level of
OPN expression was observed in the medulla (data not trols and OLETF-ramipril treated rats were observed in
medullary regions (data not shown).shown), which was confined to the tubular epithelium,
collecting ducts and uroepithelial lining cells. However,
Effects of ramipril on TGF-1 mRNA andmost cortical structures were negative for OPN mRNA
protein expressionand protein, although occasional weak expression was
detected in some tubular epithelial cells of the distal As shown in Figure 5B, TGF-1 mRNA expression
tubules and parietal epithelial cells of Bowman capsules was higher in OLETF controls than in LETO rats (507

and the renal cortex. In contrast, the levels of OPN 81 vs. 106 
 8%, P  0.001) and this was abrogated by
mRNA and protein in OLETF controls were dramati- ramipril treatment (240 
 38 vs. 507 
 81%, P  0.001).
cally elevated in tubular epithelium and Bowman’s cap- Consistently, TGF-1 protein expression, as detected
sule cells. The most striking changes were seen in the by immunohistochemistry, was rarely observed in the
renal cortex (Fig. 6, C1 and C2), which normally ex- kidneys of LETO rats, whereas its immunoreactivity was
pressed very little constitutive OPN. Interestingly, the markedly increased in the OLETF controls and was
sites of strong OPN mRNA and protein expressions were mainly localized to areas of cortical tubule and intersti-
tium (Fig. 7). With ramipril treatment, immunoreactivitylocalized to areas of severe tissue damage, including atro-
phied tubules. In OLETF rats treated with ramipril for of TGF-1 in the OLETF controls was reduced when
compared with the untreated OLETF rats.nine months, both OPN mRNA and protein expressions
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Fig. 3. Photomicrographs of PAS staining and semiquantitative analy-
sis of glomerulosclerosis in each group. (A) Normal glomerulus. (B) Ar- Fig. 4. Extent of tubulointerstitial fibrosis in LETO and OLETF rats
teriolar hyalinosis. (C ) Widening of glomerular basement membranes. treated with ramipril or vehicle during nine months. (A) LETO controls.
(D) Nodular lesions or glomerulosclerosis. #P  0.001 vs. LETO con- (B) LETO-ramipril treated rats. (C ) OLETF controls. (D) OLETF-
trols; ##P  0.004 vs. OLETF controls. Original magnification 	400. ramipril treated rats. OLETF controls showed renal tubular atrophy,
inflammatory cell infiltration, and extracellular matrix deposition,
whereas blockade of angiotensin II with ramipril significantly attenuated
these structural changes. #P  0.001 vs. LETO controls; ##P  0.002
vs. OLETF controls. Masson trichrome staining, original magnificationEffects of ramipril on macrophage infiltration
	100.
Macrophages, as detected by immunohistochemical
staining for ED-1, were rarely observed within the tubu-
lar interstitium of LETO rats, but their numbers were
ED-1 positive cells (r  0.560, P  0.01) and the tubulo-significantly higher in the OLETF controls (2.6 
 0.5 vs.
interstitial fibrosis score (r  0.500, P  0.025).21.0 
 2.8, respectively; P  0.001), especially in fibrotic
lesions (Fig. 8). Ramipril markedly decreased the num-
ber of ED-1 positive cells in the OLETF controls (9.6 
 DISCUSSION
1.0 vs. 21.0 
 2.8, respectively; P  0.001). Our results clearly demonstrate that OPN mRNA and
protein expressions are markedly up-regulated in OLETF
Association between osteopontin expression and diabetic rat kidneys, in association with macrophage in-
the number of ED-1 positive cells and flux and tubulointerstitial fibrosis. With ramipril treat-
tubulointerstitial fibrosis ment, OPN expression was significantly suppressed, and
The relationship between OPN mRNA expression and this coincided with reductions in macrophage infiltration
macrophage accumulation and tubulointerstitial fibrosis and tubulointerstitial fibrosis. These findings suggest that
was analyzed in the OLETF rats (N  20; Fig. 9). OPN the up-regulation of OPN may be responsible for tubulo-
interstitial inflammation and fibrotic formation, and thatmRNA expression correlated well with the numbers of
Li et al: Osteopontin in OLETF diabetic rats460
Fig. 5. Northern blot and quantitative analyses of osteopontin (A) and transforming growth factor-1 mRNAs (B). Northern blots showing that
OPN and TGF-1 mRNAs were markedly up-regulated in OLETF controls, whereas treatment with ramipril for nine months abrogated this
action. OPN and TGF-1 mRNAs were normalized for GAPDH mRNA (OPN, TGF-1/GAPDH ratio, %). #P  0.001 vs. LETO controls;
##P  0.005 vs. OLETF controls.
OPN expression is regulated by the RAS in diabetic sion is regulated by the RAS, and that it is associated
with tubulointerstitial injury [21, 28]. Ang II has beennephropathy during late stages.
Osteopontin is a potent chemotactic and adhesive fac- shown to up-regulate OPN expression in proximal tubu-
lar cells in vitro [38, 39], and Ang II infusion into ratstor for macrophages [8, 9, 17], and there is overwhelming
evidence that the up-regulation of tubular OPN expres- induces OPN expression and the accumulation of tubulo-
interstitial macrophages and fibrosis [40]. In addition,sion is strongly associated with macrophage infiltration
subsequent to tubulointerstitial injury in experimental the blockade of Ang II by using either angiotensin-con-
verting enzyme (ACE) inhibitors or Ang II type 1 (AT1)studies [18–21, 29] and in human patients with kidney
diseases [30–32]. This concept is confirmed by studies receptor antagonists may blunt the OPN expression ac-
companying reduced macrophage influx and tubulointer-using OPN-gene knockout mice [33], and antisense-treated
or anti-OPN antibody-treated animals [34–37], demon- stitial injury [21, 28]. The current study and previous
reports strongly implicate a role for Ang II in the up-strating a marked reduction in macrophage influx and
renal impairment. The results of the present study show regulation of OPN in this model, and ramipril may act
in a renoprotective manner by suppressing inflammatorythat tubular OPN expressions, as detected by Northern
blots, in situ hybridization, and immunohistochemistry, cytokine OPN expression.
The mechanism by which Ang II stimulates OPN ex-was dramatically up-regulated in OLETF rats in parallel
with the number of ED-1 positive cells, as well as with pression in renal tubules in this model may be direct or
indirect. Ang II may act directly to stimulate tubularthe development of tubulointerstitial fibrosis. Thus, in-
creased OPN expression may be involved in the develop- expression of OPN [38–40]. However, a number of indi-
rect mechanisms also should be considered. First, sys-ment of tubulointerstitial inflammation associated with
diabetic nephropathy in OLETF rats. temic hypertension in this model may be involved in the
up-regulation of OPN, as other antihypertensive drugsIt is interesting that the up-regulation of OPN expres-
sion in diabetic rat kidneys was significantly suppressed also suppress OPN expression [41]. Second, Ang II is
able to induce TGF- expression [42], a key profibroticby blocking the RAS with ramipril. This reduction in
OPN expression correlated well with the decreased num- cytokine involved in the pathogenesis of diabetic ne-
phropathy [24, 43], or proteinuria [44]. Both of theseber of ED-1 positive cells (r  0.560, P  0.01) and with
levels of tubulointerstitial fibrosis (r  0.500, P  0.05). pathways have been shown to up-regulate OPN expres-
sion [45, 46]. Third, high glucose enhances Ang II genera-This is consistent with previous reports that OPN expres-
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Fig. 7. Photomicrographs of immunohistochemistry of TGF-1 in kid-
ney cortex of LETO and OLETF rats treated with ramipril or vehicle
for nine months. (A) LETO controls. (B) LETO–ramipril treated rats.
(C ) OLETF controls. (D) OLETF-ramipril treated rats. TGF-1 pro-
tein was almost negative in cortical tubules and interstitium of LETO
rats, whereas its immunoreactivity was significantly increased in OLETF
controls. With ramipril treatment, the increased TGF-1 expression was
decreased. Original magnification 	100.
opposite result was observed from type I DM. Fischer
et al described a time-dependent up-regulation of OPN
expression in renal cortical tissue after the induction of
diabetes using streptozotocin (STZ), and this increased
further with ramipril administration [48]. Comparing the
two animal models, the STZ-induced diabetic animal is
characterized by expansion of the glomerular or tubular
basement membrane and by mild tubular changes with-
out the development of hypertension [49]. In our diabetic
Fig. 6. Photomicrographs of immunohistochemistry (A1-D1) and in
model, however, typical diabetic glomerulopathy, pro-situ hybridization (A2-D2) of osteopontin in kidney cortex of LETO
and OLETF rats treated with ramipril or vehicle for nine months. Both nounced tubulointerstitial fibrosis, and hypertension de-
mRNA and protein of OPN were absent in cortical tubular epithelium veloped over nine months. Thus, fundamentally differentof LETO rats (A and B). In the OLETF controls, however, their expres-
pathways may account for the progression of renal injurysion was markedly increased (C). With ramipril treatment, these increased
OPN mRNA and protein expressions were abrogated (D). Original mag- between insulin-dependent (IDDM) and non-insulin–
nification 	100. dependent (NIDDM) diabetes mellitus. Further studies
are required to resolve this issue.
One of the considerations in interpreting our study is
the duration of study. The prolonged duration of this ex-tion in primary cultures of rat mesangial cells, which in
periment (nine months) in such relatively short-lived ani-turn stimulates TGF-1 production [47], leading us to
mals may create a model of renal disease of age, in addi-postulate an interaction between Ang II and high glucose
tion to that of simple diabetic nephropathy. Age-relatedstatus. In the present study, blocking Ang II activity
renal disease may mimic that of diabetic nephropathy,markedly abrogated the up-regulation of renal TGF-1
in which renal insufficiency, glomerulosclerosis and tu-expressions, proteinuria, and systolic blood pressure.
bulointerstitial fibrosis as well as up-regulation of OPNTherefore, OPN expression must be regulated by several
expression and macrophage infiltration are observedfactors (Ang II, TGF-1, proteinuria, systemic hyperten-
[50, 51]. Therefore, there is a possibility that changes insion, high glucose), and Ang II must play a critical role
renal function, histology, and OPN expression in thisin the expression of OPN in this model.
model are associated with aging nephropathy along withOur study revealed that OPN expression increased in
rat kidneys with type II diabetes mellitus (DM), but the diabetic nephropathy. In addition, blockade of the RAS
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Fig. 8. Immunohistochemical staining of macrophages and semiquanti-
tative counts of ED-1 positive cells within the tubular interstitium in
each group. (A) LETO controls. (B) LETO–ramipril treated rats. (C ) Fig. 9. Relationship between osteopontin mRNA expression and mac-
OLETF controls. (D) OLETF-ramipril treated rats. OLETF controls rophage accumulation and tubulointerstitial injury. The expression of
revealed focal ED-1 positive cell accumulation within the tubular inter- OPN mRNA correlated well with the number of ED-1 positive cells
stitium compared with LETO rats, especially in injured areas. Ramipril (A) and the tubulointerstitial fibrosis score (B) in the OLETF rats.
significantly decreased the number of ED-1 positive cells. Original mag- Data are from 20 animals with diabetes analyzed using Pearson single
nification	100. #P 0.001 vs. LETO controls; ##P 0.001 vs. OLETF correlation coefficient. In A, r  0.560 and P  0.01; in B, r  0.500
controls. and P  0.05.
Reprint requests to Byung Kee Bang M.D., PhD., Department ofis effective in preventing age-related renal diseases [52].
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